Islet transplantation: Present clinical situation and future aspects

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Bretzel, R G ^a   Brendel, M ^a   Eckhard, M ^a   Brandhorst, D ^a   Jaeger, C ^a   Hatziagelaki, E ^a   Federlin, K ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Alloimmunity; Autoimmunity; End stage renal disease; Gene therapy; Immunosuppression; Immunotolerance; Islet transplantation; Kidney transplantation

Indexed keywords

ARTICLE; FUTUROLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

GRAFT REJECTION; HUMANS; INTERNATIONAL COOPERATION; ISLETS OF LANGERHANS TRANSPLANTATION; REGISTRIES;

EID: 0034975224     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18597     Document Type: Article

References (66)

1. Insulin independence after islet transplantation into type I diabetic patient
2. Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients. Report of six cases
3. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus
4. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin
5. Clinical islet transplantation in diabetes mellitus - Report of the Islet Transplant Registry and the Giessen Center experience
6. Long-term function (6 years) of islet allografts in type 1 diabetes
7. New protocol toward prevention of early human islet allograft failure
8. Improved survival of intraportal pancreatic islet cell allografts in patients with type 1 diabetes mellitus by refined peritransplant management
9. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with type I diabetes mellitus
10. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
11. Automated method for isolation of human pancreatic islets
12. C-peptide improves autonomic nerve function in IDDM patients
13. New aspects of C-peptide physiology
14. Proinsulin C-peptide - Biological activity?
15. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide
16. Isokinetic gradients: A new approach to reduce islet graft immunogenicity
17. Influence of donor data and organ procurement on human islet isolation
18. Impact of cold ischemia and timing of intraductal collagenase distension on human islet yield, purity, viability, and survival in low temperature culture
19. Body mass index is an important determinant of human islet isolation outcome
20. Toxic effects of superoxide hydrogen peroxide and nitric oxide on human and pig islets
21. Isolated human pancreatic islets in vitro activate human complement
22. Effects of bicarbonate and amino acid buffered media on survival and viability of long-term bulk cultured human islets
23. Prevention of primary nonfunction after porcine islet allotransplantation
24. Assessment of intracellular insulin content during all steps of human islet isolation procedure
25. Large variability of the intracellular ATP content of human islets isolated from different donors
26. Cytokine mRNA expression in peripheral blood cells of immunosuppressed human islet transplant recipients
27. Endotoxin-mediated activation of cytokine production in human PBCs by collagenase and Ficoll
28. Evidence for a significant correlation of donor pancreas morphology on the yield of isolated purified human islets
29. Incompatibility between human blood and isolated islets of Langerhans. A finding with implications for clinical intraportal islet transplantation?
30. Islet isolation from the pancreas of large mammals and humans: 10 Years of experience
31. Islet cell transplantation in diabetes mellitus - From bench to bedside
32. Percutaneous transhepatic catherization of the portal vein: A combined CT- and fluoroscopy-guided technique
33. Improved survival of intraportal pancreatic islet cell allografts in patients with type 1 diabetes mellitus by refined peritransplant management
34. Type I diabetes mellitus: A chronic autoimmune disease
35. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation
36. Recurrent diabetes mellitus in the pancreas iso- and allograft: A light and electron microscopic and immunohisto-chemical analysis of four cases
37. Recurrence of autoimmune diabetes in recipients of cadaveric pancreatic grafts
38. Evidence of recurrent autoimmunity in human allogeneic islet transplantation
39. Islet cell antibodies and GAD 65 antibodies in IDDM patients undergoing kidney and islet after kidney transplantation
40. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression
41. Progressive islet graft failure occurs significantly earlier in autoantibody positive than in autoantibody negative IDDM recipients of intrahepatic islet allografts
42. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes
43. Prevention of autoimmune islet allograft destruction by engraftment of donor T cells
44. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients
45. Islet transplantation for patients with type 1 diabetes
46. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells
47. GAD, a single autoantigen for diabetes
48. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses
49. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients
50. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function
51. Prolongation of rat islet allograft survival by the immunosuppressive agent leflunomide
52. Islet transplantation in immunoseparating membranes for treatment of insulin-dependent diabetes mellitus
53. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation
54. Synergistic effect of microencapsulation and immunoalteration on islet allograft survival in bioartificial pancreas
55. Immunosuppressive effects of human CTLA4Ig in non-human primate model of allogeneic pancreatic islet transplantation
56. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD 154
57. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD 154
58. Gene therapy for diabetes: Strategies for β-cell modification and replacement
59. Targeting autoimmune diabetes with gene therapy
60. Growth factor / matrix-induced proliferation of human adult beta cells
61. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice
62. + cells derived from human islets
63. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells
64. Biological alternatives to insulin therapy
65. Scientific and political impediment to successful islet transplantation